Prevention of Events with Angiotensin-Converting Enzyme Inhibition (The PEACE study design)

Marc A. Pfeffer, Michael Domanski, Yves Rosenberg, Joel Verter, Nancy Geller, Paul Albert, Judith Hsia, Eugene Braunwald

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Abstract

The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial is an 8,100 patient, randomized, double-blind, placebo- controlled trial designed to determine the usefulness of angiotensin- converting enzyme (ACE) inhibitors in treating coronary patients with preserved left ventricular ejection fraction. The hypothesis being tested in this trial is that patients with coronary disease and ejection fraction ≤40% who are treated with ACE inhibitors will experience a reduction in the incidence of cardiovascular death, nonfatal myocardial infarction, or a revascularization procedure compared with patients treated with conventional therapy. The design of the PEACE trial is described herein.

Original languageEnglish
Pages (from-to)25-30
Number of pages6
JournalAmerican Journal of Cardiology
Volume82
Issue number3 A
DOIs
StatePublished - 6 Aug 1998
Externally publishedYes

Fingerprint

Dive into the research topics of 'Prevention of Events with Angiotensin-Converting Enzyme Inhibition (The PEACE study design)'. Together they form a unique fingerprint.

Cite this